Trials / Temporarily Not Available
Temporarily Not AvailableNCT06784297
INTERMEDIATE-SIZE PATIENT POPULATIONS EXPANDED ACCESS TO TREATMENT FOR SARCOPENIC OBESITY
- Status
- Temporarily Not Available
- Phase
- —
- Study type
- Expanded Access
- Enrollment
- —
- Sponsor
- Immunis, Inc. · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- —
Summary
The expanded access is designed for patients requesting the treatment, and whose medical condition may benefit from treatment, but are unable to participate in any other IMM01-STEM clinical trial in their physician's opinion for reasons that include: (1) They do not meet enrollment criteria, or (2) They cannot perform the assessment of outcomes, or (3) The trial site is not geographically accessible.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| BIOLOGICAL | IMM01-STEM | The individuals receiving expanded access will receive a treatment identical to the most convenient regimen in the current clinical trial (STEM-META). The treatment will consist of one i.m. injection per week containing 2 mg of total protein in 2 mL, for a total of 4 weeks (4 injections). As more efficacy information accumulates, the treatment plan will be adjusted accordingly to maximize the potential benefit. |
Timeline
- First posted
- 2025-01-20
- Last updated
- 2026-03-06
Source: ClinicalTrials.gov record NCT06784297. Inclusion in this directory is not an endorsement.